Form 4: Akari Therapeutics Director Acquires 79,684,000 Stock Options
SEC Form 4 Filing
Director Samir Rashmikant Patel acquired 79,684,000 stock options in Akari Therapeutics Plc on October 31, 2024.
Summary
- On October 31, 2024, Samir Rashmikant Patel, a director of Akari Therapeutics Plc, acquired 79,684,000 stock options.
- The options have an exercise price of $0.001255 per ordinary share.
- The options are exercisable from October 31, 2024, and expire on October 31, 2034.
- The ordinary shares may be represented by American Depositary Shares (ADS), where each ADS currently represents 2,000 ordinary shares.
Sentiment
Score: 6
Explanation: The sentiment is neutral to slightly positive. A director acquiring a large number of stock options can be seen as a vote of confidence, but it's a routine transaction.
Positives
- A director's acquisition of a significant number of stock options could be interpreted as a positive sign of confidence in the company's future prospects.
Industry Context
Form 4 filings are standard disclosures required by the SEC when insiders (directors, officers, and 10% owners) of a publicly traded company buy or sell the company's securities. This filing indicates a change in beneficial ownership.
Stakeholder Impact
- Shareholders may view the director's stock option acquisition as a positive signal.
Key Dates
| Date | Description |
|---|---|
| 10/31/2024 | Date of earliest transaction: Director acquired 79,684,000 stock options. |
| 10/31/2024 | Date the stock options are exercisable. |
| 10/31/2034 | Expiration date of the stock options. |
| 11/01/2024 | Date of signature on the Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.